Biotechnology and Pharmaceuticals · us
Directly Intercepting Autoimmune Signaling: Yarrow Launches Phase 2 Trial of YB-101
After completing its merger with VYNE and securing approximately $200 million in funding, Yarrow has begun testing an antibody that directly blocks TSHR; the first proof-of-concept data are expected in the second half of 2027.
Graves’ disease and thyroid eye disease can occur in the same patient and share an underlying pathological process involving abnormal activation of the thyroid-stimulating hormone receptor (TSHR). Newly formed Yarrow Bioscience is now advancing this common target into a mid-stage clinical trial to determine whether directly blocking TSHR can control both hyperthyroidism and orbital disease.
Yarrow announced that it has completed its merger with VYNE Therapeutics and closed the previously planned private placement totaling approximately $200 million. Following the merger, the company retained the Yarrow Bioscience name and plans to trade on Nasdaq under the ticker YARW. The company estimates that its current funding can support operations through 2028, although this financial outlook remains dependent on trial progress and actual expenditures.
Lead candidate YB-101 is an anti-TSHR monoclonal antibody designed for subcutaneous administration. In patients with Graves’ disease, autoantibodies abnormally stimulate TSHR, causing the thyroid to produce excessive hormones; the associated signaling is also implicated in inflammation and remodeling of orbital tissues. Rather than addressing only downstream symptoms, YB-101 is intended to block the disease-driving signal at the receptor, but this proposed mechanistic advantage has not yet been confirmed in a controlled trial.
The Phase 2 trial, in which dosing has begun, consists of two parts and enrolls patients with Graves’ disease, whether or not they also have thyroid eye disease. The first stage is a randomized, blinded, placebo-controlled Phase 2a proof-of-concept study expected to enroll a total of 32 participants across four cohorts. It will assess safety, pharmacokinetics, pharmacodynamics, and efficacy measures over 24 weeks, including the proportion of patients who regain normal thyroid function after discontinuing antithyroid medication and orbital changes in those with concurrent eye disease.
The company expects to report Phase 2a results in the second half of 2027 and will use them to select the dose and dosing interval. The Phase 2b dose-ranging portion, involving approximately 200 participants, is tentatively scheduled to begin in the first half of 2028. YB-101 has received Fast Track designation from the U.S. Food and Drug Administration, but the designation is primarily intended to expedite development and interactions during review and does not mean that efficacy, safety, or marketing approval has been confirmed.
Yarrow’s Chinese licensing partner, Changchun GeneScience Pharmaceuticals, is also conducting a Phase 1 study under the name GenSci-098. The company said that a single-ascending-dose trial in thyroid eye disease showed dose-related mechanistic signals and preliminary clinical responses, with no clinically meaningful safety differences compared with placebo. However, the announcement did not provide complete data, sample size, or peer-reviewed results. Multiple-dose data are likewise expected in the second half of 2027, when more evidence will be available to determine whether this receptor-blocking strategy warrants larger-scale development.